From PharmD to Pharmacogenomics Test Developer: Dr. Thierry Dervieux’s Story of Revolutionizing Healthcare Through Precision Medicine for Immune Modulated Inflammatory Diseases | PGx For Pharmacists

Becky Winslow, BS, PharmD Host and Pharmacogenomics Medical Science Liaison; Behnaz Sarrami, MS, PharmD, Host and Pharmacogenomics Medical Science Liaison; Thierry Dervieux, PharmD, PhD, Chief Scientific Officer at Prometheus Laboratories

In this episode of the PGX for Pharmacists Podcast, Dr. Thierry Dervieux, Dr. Behnaz Sarrami, and I discuss Dr. Dervieux’s career as a PharmD,
PhD, and chief scientific officer who has designed a pharmacogenomics test prescribers may use to optimize biosimilars for autoimmune gastrointestinal diseases. Dr. Dervieux will illustrate to our audience pharmacogenomics’ potential beyond Tier 1 and 2 genetic testing by describing the clinical validity and utility of his laboratory’s suite of tests in the autoimmune gastrointestinal disease diagnosis and treatment market. Behnaz and I hope this episode will inspire pharmacists interested in pharmacogenomics to think beyond the boxed PGx test most laboratories offer when they think about PGx and consider all the biological systems in which genetics impacts drugs’ efficacy and safety.

Disclaimer:
Behnaz Disclaimer: These are my personal views and opinions, and I am not speaking on behalf of Castle Biosciences, Inc. Becky Disclaimer: These are my personal views and opinions, and I am not speaking on behalf of any other entity.

 

Transcription:

1
00:00:06,190 --> 00:00:19,620
You're listening to the Pharmacy podcast Network in a world where one size fits all medications dominate the pharmaceutical industry.

2
00:00:20,079 --> 00:00:24,750
Precision medicine brings a ray of hope for those seeking customized health care.

3
00:00:25,350 --> 00:00:32,830
Pharmacists have a unique opportunity to help people in need of specialized testing to ensure medications work as intended.

4
00:00:33,540 --> 00:00:44,680
Welcome to PGX for pharmacists where we unravel the wonders of precision medicine and its potential to revolutionize the way we approach pharmacy care.

5
00:00:45,169 --> 00:00:52,790
Get ready to uncover the secrets behind pharmacogenomics and how it's transforming lives one genome at a time.

6
00:00:52,799 --> 00:00:53,189
Hello,

7
00:00:53,200 --> 00:00:53,950
everyone.

8
00:00:54,159 --> 00:00:55,080
I'm your host,

9
00:00:55,090 --> 00:00:56,389
Doctor Becky Winslow.

10
00:00:56,409 --> 00:01:09,860
And you're listening to the PGX for Pharmacist podcast that we magazine recognized in 2021 as the ninth most listened to genetics podcasts in the world on the PGX for Pharmacist podcast.

11
00:01:09,870 --> 00:01:16,690
We explore all things pharmacogenomics related and our mission is to educate and advocate for PGX.

12
00:01:16,769 --> 00:01:23,849
We accomplish this mission through exclusive interviews with highly qualified and well experienced pharmacogenomics.

13
00:01:23,860 --> 00:01:29,720
Industry leaders such as today's special guest and my name is Baas Sami,

14
00:01:29,730 --> 00:01:32,739
the co-host of PGX for Pharms podcast,

15
00:01:32,750 --> 00:01:33,860
Pharmacogenomics,

16
00:01:33,870 --> 00:01:36,819
medical science liaison and a mentor to pharmacist.

17
00:01:36,889 --> 00:01:40,239
Connect with us on linkedin and let's get a conversation going.

18
00:01:40,269 --> 00:01:46,720
We want to hear from you and how you're impacting pharmacogenomic stakeholders and what you have learned throughout your journey.

19
00:01:48,510 --> 00:01:49,010
Ok.

20
00:01:49,019 --> 00:01:50,819
So without any further ado,

21
00:01:50,839 --> 00:01:54,769
I'm extremely pleased to introduce to our audience.

22
00:01:54,919 --> 00:01:56,059
Doctor Theory Devo,

23
00:01:57,239 --> 00:02:01,129
the Chief Scientific Officer at Prometheus Laboratories,

24
00:02:01,139 --> 00:02:08,139
and Perme Prometheus Laboratories is a reference clinical laboratory that's focused on the diagnosis,

25
00:02:08,149 --> 00:02:13,330
prognosis and monitoring of immune mediated inflammatory diseases.

26
00:02:13,970 --> 00:02:14,229
So,

27
00:02:14,240 --> 00:02:14,649
thank you,

28
00:02:14,660 --> 00:02:17,759
Doctor De for joining us on the podcast.

29
00:02:17,770 --> 00:02:18,589
Today.

30
00:02:18,600 --> 00:02:23,190
I'm excited to share your and Prometheus's story with our audience.

31
00:02:23,649 --> 00:02:25,630
Um in particular,

32
00:02:25,639 --> 00:02:45,369
I'm excited about you sharing your career journey as a farm D phd and Chief scientific officer and designer of the Predictor PK AD A which is a precision guided dosing test for the optimization of Humira Remicade and their bio cylinders.

33
00:02:46,119 --> 00:02:46,449
So,

34
00:02:46,460 --> 00:03:04,220
one of Bana's and my main goals for this episode of the PGX for Pharmacist podcast is to expand our audience's notion of what a PGX test looks like and to inspire them to think bigger than the traditional box PGX test.

35
00:03:04,229 --> 00:03:08,020
Most of them or most of you are uh familiar with.

36
00:03:09,020 --> 00:03:09,429
So,

37
00:03:09,440 --> 00:03:22,179
Doctor D uh I'd like to start the podcast by having our guests um introduce themselves and elaborate on how you are a pharmacogenomics expert.

38
00:03:23,619 --> 00:03:23,800
Yeah,

39
00:03:23,809 --> 00:03:24,250
thank you,

40
00:03:24,259 --> 00:03:25,759
Becky for having me.

41
00:03:25,770 --> 00:03:26,850
Uh uh Yes.

42
00:03:26,860 --> 00:03:27,289
So I am a,

43
00:03:27,300 --> 00:03:30,820
I am a pharmacist uh with uh a family who is a,

44
00:03:30,830 --> 00:03:33,039
a doctorate in pharmacokinetics.

45
00:03:33,539 --> 00:03:44,520
Uh I completed my studies in France and I came as a postdoc uh fellow uh to work in the United States about 20 years ago to work on the pharmacogenomic of anti cancer agents,

46
00:03:44,929 --> 00:03:49,160
uh primarily uh six Maturin as well as methotrexate.

47
00:03:49,169 --> 00:03:50,550
After my post doc,

48
00:03:50,770 --> 00:03:52,960
uh I moved uh in industry for promet.

49
00:03:53,490 --> 00:04:01,429
So I have a large experience in uh uh the implementation of pharmacogenetics testing in immune mediated inflammatory disease.

50
00:04:01,509 --> 00:04:12,550
Our lab Rome was the first uh clinical laboratory in the United States to offer the fin uh metyl transfer genotyping as well as the thin metabolites.

51
00:04:12,559 --> 00:04:13,029
So,

52
00:04:13,050 --> 00:04:21,989
uh uh of uh of 70 publications in the field and uh I'm very uh very excited to have uh to be on the postcard with you uh uh today.

53
00:04:23,660 --> 00:04:24,220
All right.

54
00:04:24,230 --> 00:04:27,359
So thank you for qualifying yourself as an expert.

55
00:04:27,369 --> 00:04:27,619
So,

56
00:04:27,630 --> 00:04:32,839
let's jump right in and delve into your current PGX work.

57
00:04:32,850 --> 00:04:33,279
So,

58
00:04:33,489 --> 00:04:36,540
if you'll tell us um a little about Prometheus,

59
00:04:36,549 --> 00:04:38,000
specifically,

60
00:04:38,010 --> 00:04:40,350
what is Prometheus's mission?

61
00:04:40,359 --> 00:04:43,799
And how are you guys going about accomplishing your mission?

62
00:04:44,760 --> 00:04:44,980
Yeah,

63
00:04:44,989 --> 00:04:45,700
sure.

64
00:04:45,709 --> 00:04:47,459
Uh So Promet is a,

65
00:04:47,470 --> 00:04:52,790
is a reference uh clinical laboratory based in Southern California in San Diego.

66
00:04:53,230 --> 00:04:56,809
Uh The company has been there for uh over 25 years.

67
00:04:56,820 --> 00:05:03,950
We are uh specialize in the differential diagnosis of autoimmune G I disease uh disorders,

68
00:05:04,059 --> 00:05:06,019
uh gastrointestinal disorder,

69
00:05:06,230 --> 00:05:08,619
uh and inflammatory bowel disease.

70
00:05:08,980 --> 00:05:10,299
And over the years,

71
00:05:10,309 --> 00:05:16,600
we have developed a portfolio of a differentiated solution to facilitate the diagnosis,

72
00:05:16,609 --> 00:05:17,470
the prognosis,

73
00:05:17,480 --> 00:05:18,429
the monitoring,

74
00:05:18,660 --> 00:05:21,910
as well as therapy selection with pharmacogenetics testing,

75
00:05:21,920 --> 00:05:24,730
which we are offering to our clinical laboratory.

76
00:05:24,829 --> 00:05:26,350
And most importantly,

77
00:05:26,410 --> 00:05:27,299
uh recently,

78
00:05:27,309 --> 00:05:35,660
we are uh uh developing some uh uh testing solution with the credit topic care test to optimize treatment to uh biologics.

79
00:05:36,470 --> 00:05:37,130
Ok.

80
00:05:37,140 --> 00:05:37,329
Well,

81
00:05:37,339 --> 00:05:37,450
that,

82
00:05:37,459 --> 00:05:38,049
that's great.

83
00:05:38,059 --> 00:05:46,100
Can you also tell us uh about the Prois Library of Precision Medicine Tests for inflammatory bowel disease for patients?

84
00:05:46,109 --> 00:05:49,230
how they benefit medication therapy management.

85
00:05:49,239 --> 00:05:56,429
Stakeholders across the IB DS patients journey from diagnosis to treatment to disease,

86
00:05:56,440 --> 00:06:02,049
monitoring through remission and how they differ from other lab tests for IBD and his treatments.

87
00:06:02,709 --> 00:06:03,209
Yes.

88
00:06:03,220 --> 00:06:03,369
So,

89
00:06:03,380 --> 00:06:04,399
so we uh our,

90
00:06:04,410 --> 00:06:10,100
our clinical laboratory offers some uh highly specialized test to facilitate the,

91
00:06:10,109 --> 00:06:16,779
the diagnostic of uh to facilitate the differential diagnosis of uh uh inflammatory bowel disease.

92
00:06:16,790 --> 00:06:22,359
So we are following uh testing solution with uh serological testing,

93
00:06:22,529 --> 00:06:23,799
for example,

94
00:06:23,809 --> 00:06:38,410
uh uh piana as as as well as uh macro microbial uh uh antibodies that are present uh uh in Crohn's disease as well as uh over uh auto uh auto antibodies that are present in er colitis.

95
00:06:39,339 --> 00:06:43,684
These are conditions that are uh uh somewhat difficult to treat.

96
00:06:43,704 --> 00:06:49,994
Uh And uh we are uh uh offering those tests to uh help uh gastroenterologist.

97
00:06:50,015 --> 00:06:51,114
Uh uh first of all,

98
00:06:51,125 --> 00:07:03,434
to establish a differential diagnosis of IBD as compared to other uh condition typically uh uh irritable bowel syndrome as well as over gastrointestinal disorder.

99
00:07:03,445 --> 00:07:05,635
When the diagnostic is established,

100
00:07:05,910 --> 00:07:31,839
uh we offer uh testing to uh establish a prognosis where we're gonna in inform the clinician that the patient has a more aggressive uh disease that will require more aggressive treatment where uh we can uh provide the testing solution to initiate uh uh the most appropriate therapy for uh for the patient uh with uh a testing where we are uh basically uh you know,

101
00:07:31,850 --> 00:07:36,559
establish de determining some genotyping with the fit transferal genotyping.

102
00:07:36,570 --> 00:07:37,279
For example,

103
00:07:37,290 --> 00:07:40,250
where we can uh indicate that the patient is,

104
00:07:40,260 --> 00:07:45,079
is likely uh to present with a side effect to those medication.

105
00:07:45,399 --> 00:07:46,170
And once you know,

106
00:07:46,179 --> 00:07:47,799
the the treatment is initiative,

107
00:07:47,809 --> 00:08:16,089
we have a portfolio of solution uh to facilitate the monitoring of the disease of the inflammatory bowel disease as well as the dosing optimization with uh uh the answer test which uh measure blood level uh for uh uh monoclonal antibodies that are indicated in the treatment of IB start with starting with Infliximab Adalimumab as well as uh Tein and vidal.

108
00:08:16,980 --> 00:08:24,040
So we have a comprehensive portfolio to uh to surround the clinician with uh a variety of testing solution.

109
00:08:24,049 --> 00:08:30,250
With our goal being to improve the uh the outcome uh of patients with uh with diabetes.

110
00:08:30,260 --> 00:08:34,520
And I think that the pharmacist has a very important role to play from that perspective.

111
00:08:35,179 --> 00:08:36,039
So theory,

112
00:08:36,049 --> 00:08:40,239
could you elaborate for us more on the predictor test?

113
00:08:40,249 --> 00:08:42,758
Um especially since you designed that test,

114
00:08:42,768 --> 00:08:44,218
we'd really like to know,

115
00:08:44,489 --> 00:08:45,039
um you know,

116
00:08:45,049 --> 00:08:49,638
what did that take and what role does it play in your suite of testing?

117
00:08:51,049 --> 00:08:51,270
Yeah.

118
00:08:51,280 --> 00:08:51,890
Sure.

119
00:08:51,900 --> 00:08:52,510
So the,

120
00:08:52,520 --> 00:08:52,570
the,

121
00:08:52,580 --> 00:08:52,989
the,

122
00:08:53,000 --> 00:08:53,229
the,

123
00:08:53,239 --> 00:08:59,960
the predictor test is uh uh is uh is utilized when the patient is receiving treatment.

124
00:09:00,280 --> 00:09:18,190
It's been speci specifically designed to optimize uh biological uh uh disease modifiers such as Infliximab adalimumab that are co therapies in the treatment of inflammatory bowel disease as well as other immune uh mediated inflammatory.

125
00:09:18,200 --> 00:09:21,549
This is what the test does is to you connect the blood specimen,

126
00:09:22,229 --> 00:09:23,049
uh you know,

127
00:09:23,059 --> 00:09:24,750
with dosing information.

128
00:09:25,039 --> 00:09:41,989
And what we do is to uh uh provide guidance uh to clinician with uh respect of the best dose to give in order to achieve the best the level which is the most consistent with uh uh the disease control that needs to be achieved for the patient.

129
00:09:42,169 --> 00:09:43,729
Typically a vast majority,

130
00:09:43,739 --> 00:09:46,159
about two third of a third to two third,

131
00:09:46,169 --> 00:09:54,669
a third of patient uh tend to be uh uh unresponsive uh to this uh very expensive medication.

132
00:09:54,989 --> 00:09:57,960
Uh Not because they don't have the uh you know,

133
00:09:57,969 --> 00:09:59,289
typically because they have a,

134
00:09:59,299 --> 00:09:59,590
you know,

135
00:09:59,599 --> 00:10:05,599
pharmacokinetic uh suboptimal pharmacokinetic uh that makes them uh you know,

136
00:10:05,609 --> 00:10:09,440
unresponsive because uh not enough drug has been given.

137
00:10:09,450 --> 00:10:18,469
So what we do with a predictor test is to basically estimate the pa the pharmacokinetic uh parameter for the patient.

138
00:10:18,750 --> 00:10:24,729
And from then uh re report the best dose uh to give in order to achieve the,

139
00:10:24,760 --> 00:10:31,570
the level which is consistent with the uh the most uh uh effective disease control to be achieved for the patient.

140
00:10:32,169 --> 00:10:33,059
So we are offering,

141
00:10:33,070 --> 00:10:38,049
we have developed a test for the Infliximab as well as Adalimumab which is Humira,

142
00:10:38,909 --> 00:10:41,309
but these are antimony causes factor.

143
00:10:41,460 --> 00:10:49,549
And we are also developing the test for vidur as well as uh is that are widely used also in the treatment of,

144
00:10:49,559 --> 00:10:51,969
of uh inflammatory bubble disease.

145
00:10:51,979 --> 00:10:52,669
Wow,

146
00:10:52,679 --> 00:10:55,450
uh for MET is a suite of tests.

147
00:10:55,460 --> 00:11:00,940
Goes well beyond um the PGX testing that our audience is most familiar with,

148
00:11:01,299 --> 00:11:08,679
uh which typically only includes snips for cyp genes and some pharmacodynamic genes.

149
00:11:08,690 --> 00:11:31,424
This is really exciting um genes and biomarkers related to immunology are not commonly found in what I call the box PGX tests such as those uh made by large uh laboratory manufacturing companies um where the panel has a set number of genes and uh you know,

150
00:11:31,434 --> 00:11:36,054
it was developed by a larger laboratory for maybe smaller laboratories use.

151
00:11:36,729 --> 00:11:39,010
So my understanding,

152
00:11:39,020 --> 00:11:53,729
having talked with you extensively theory is that immunology has fewer PGX test available because it's actually more difficult say than oncology to research and develop tests.

153
00:11:53,739 --> 00:11:54,119
So,

154
00:11:54,130 --> 00:12:00,729
could you elaborate for our audience on the difficulties that are associated with immunology,

155
00:12:00,739 --> 00:12:05,830
research and developing tests uh for immunology versus say oncology?

156
00:12:06,330 --> 00:12:06,530
Yeah,

157
00:12:06,539 --> 00:12:07,049
sure.

158
00:12:07,059 --> 00:12:09,969
So in uh in immunology,

159
00:12:09,979 --> 00:12:11,590
as compared to oncology,

160
00:12:11,599 --> 00:12:17,169
there is no such a thing such as a somatic mutation where for example,

161
00:12:17,179 --> 00:12:18,429
you're gonna have a behalf,

162
00:12:18,440 --> 00:12:18,659
you know,

163
00:12:18,669 --> 00:12:20,349
that indicates that the patient,

164
00:12:20,679 --> 00:12:20,919
you know,

165
00:12:20,929 --> 00:12:25,239
is likely to benefit or not from some treatment in immunology.

166
00:12:25,250 --> 00:12:26,750
This is far more complicated,

167
00:12:26,760 --> 00:12:28,830
complicated for the reason,

168
00:12:29,239 --> 00:12:31,020
starting with uh the fact that,

169
00:12:31,030 --> 00:12:31,179
you know,

170
00:12:31,190 --> 00:12:36,219
the response to this uh medication uh are multifactorial.

171
00:12:36,260 --> 00:12:37,820
And the fact that uh you know,

172
00:12:37,830 --> 00:12:39,380
the mutation that uh the,

173
00:12:39,390 --> 00:12:39,619
the,

174
00:12:39,630 --> 00:12:45,190
the single nucleotide polymorphism in the GM line which uh uh you know,

175
00:12:45,200 --> 00:12:52,429
can potentially associate with uh with outcome uh uh uh uh a lo in advance,

176
00:12:52,440 --> 00:12:58,359
meaning that uh they're gonna have a weak association uh with a response to those medications.

177
00:12:58,369 --> 00:13:09,609
So there is a necessity in immunology to combine multiple genetic polymorphism together in order to achieve uh some uh performances characteristics that will make uh you know,

178
00:13:09,619 --> 00:13:09,859
the,

179
00:13:09,869 --> 00:13:10,380
the,

180
00:13:10,390 --> 00:13:10,520
the,

181
00:13:10,530 --> 00:13:13,219
the clinician uh you know,

182
00:13:13,419 --> 00:13:15,619
uh order the test and most importantly,

183
00:13:15,630 --> 00:13:15,840
the,

184
00:13:15,849 --> 00:13:16,179
the,

185
00:13:16,190 --> 00:13:17,739
the payer to pay for the test.

186
00:13:17,750 --> 00:13:20,469
So this field has been uh you know,

187
00:13:20,479 --> 00:13:20,679
is,

188
00:13:20,690 --> 00:13:21,705
is moving for,

189
00:13:21,715 --> 00:13:21,994
you know,

190
00:13:22,005 --> 00:13:24,575
there are some tests that are being developed right now.

191
00:13:24,924 --> 00:13:39,034
But the biggest challenge is to be able to achieve again the the threshold of uh of performance that makes the test is variable enough uh to be uh again ordered by the clinician and the utilize uh to the benefit of the patient.

192
00:13:39,659 --> 00:13:41,200
I couldn't agree with you more.

193
00:13:41,210 --> 00:13:53,489
Um I've worked on the payer side or market access side of pharmacogenomics and even uh with a box test for which there's um a lot of research data available,

194
00:13:53,500 --> 00:13:55,119
even with those,

195
00:13:55,130 --> 00:13:59,760
it's sometimes difficult uh to get payers um to see the value.

196
00:13:59,770 --> 00:14:01,640
So I absolutely agree with you.

197
00:14:01,940 --> 00:14:03,679
Um The fact that you guys are,

198
00:14:03,690 --> 00:14:11,789
are uh investing in producing the data necessary says a lot about your laboratory.

199
00:14:11,979 --> 00:14:12,559
Um you know,

200
00:14:12,570 --> 00:14:15,380
and how committed you are to this testing and,

201
00:14:15,390 --> 00:14:17,320
and how you believe in the testing.

202
00:14:18,039 --> 00:14:23,640
So I just want to make sure that our audience recognizes that,

203
00:14:24,359 --> 00:14:24,619
you know,

204
00:14:24,630 --> 00:14:31,820
Prometheus doesn't simply provide tests to determine if drugs for IBD will be effective and safe.

205
00:14:32,190 --> 00:14:36,900
Um And maybe what the dose of the drug should be for the patient,

206
00:14:36,909 --> 00:14:40,219
but you have that whole suite of tests.

207
00:14:40,229 --> 00:14:47,380
Um the diagnostic test for the differential diagnosis all the way through remission.

208
00:14:48,030 --> 00:14:53,390
So can you elaborate you elaborated on it some in the previous question?

209
00:14:53,400 --> 00:15:01,229
But um can you tell us the difference between how you had to actually develop the test?

210
00:15:01,520 --> 00:15:02,530
Um You didn't,

211
00:15:02,539 --> 00:15:03,059
in other words,

212
00:15:03,070 --> 00:15:10,659
purchase a test from another manufacturer with the biomarkers that you include in your testing.

213
00:15:10,669 --> 00:15:16,830
Can you elaborate on how much more difficult it is to to develop a test from scratch?

214
00:15:18,169 --> 00:15:18,320
Yeah,

215
00:15:18,330 --> 00:15:18,659
sure.

216
00:15:18,669 --> 00:15:18,809
I mean,

217
00:15:18,820 --> 00:15:22,070
this is this is challenging for multiple and first of all,

218
00:15:22,080 --> 00:15:23,130
you need to have the,

219
00:15:23,419 --> 00:15:27,450
you need to have a clinical data set available with specimen available.

220
00:15:27,460 --> 00:15:28,159
Uh you know,

221
00:15:28,169 --> 00:15:28,780
in front,

222
00:15:28,859 --> 00:15:29,770
obviously,

223
00:15:29,859 --> 00:15:30,890
available.

224
00:15:31,200 --> 00:15:35,890
Uh So we are leveraging a pro meters a large bi bank of specimen.

225
00:15:36,299 --> 00:15:37,190
Uh as I said,

226
00:15:37,200 --> 00:15:39,719
Prometheus has been founded 25 years ago.

227
00:15:39,729 --> 00:15:40,599
So over the,

228
00:15:40,760 --> 00:15:41,919
the past two decades,

229
00:15:41,929 --> 00:15:54,849
we have been able to assemble a large uh substrate of data and specimen which we are uh uh using to uh uh establish our proof of concept if you will.

230
00:15:54,859 --> 00:16:07,559
And then when we have uh identify some genetic polymorphism that are uh adequately uh associated with uh uh disease outcome and disease progression as well as uh toxicity.

231
00:16:07,969 --> 00:16:11,469
Then we are entering validation phase where we are uh you know,

232
00:16:11,570 --> 00:16:14,789
using validation cohorts where we are again,

233
00:16:14,969 --> 00:16:22,630
combining multiple modalities together uh patient demographic as well as genetic marker together with theological marker.

234
00:16:22,640 --> 00:16:23,190
Actually,

235
00:16:23,500 --> 00:16:27,419
to come up with some Multivariate models that are uh again,

236
00:16:27,429 --> 00:16:39,250
bringing the performances characteristics of the pharmacogenomic test or its combination with our marker to the level where it's supposed to be in the first place to meet uh uh payer.

237
00:16:39,650 --> 00:16:41,190
And uh obviously,

238
00:16:41,200 --> 00:16:41,760
again,

239
00:16:41,770 --> 00:16:45,320
the patient uh to the benefit of the patient and to,

240
00:16:45,330 --> 00:16:46,619
to improve its outcome,

241
00:16:46,739 --> 00:16:47,429
the outcome.

242
00:16:48,340 --> 00:16:53,380
I think what you're describing really is the future of pharmacogenomics.

243
00:16:53,390 --> 00:16:54,599
Um In other words,

244
00:16:54,609 --> 00:17:03,419
not singing out pharmacogenomics as you know the end all and be all in the treatment paradigm.

245
00:17:03,559 --> 00:17:08,040
But using a PGX test in combination with,

246
00:17:08,050 --> 00:17:09,069
like you mentioned,

247
00:17:09,250 --> 00:17:11,160
other serological tests,

248
00:17:11,170 --> 00:17:12,959
maybe other genetic tests.

249
00:17:13,290 --> 00:17:14,890
Um But you know,

250
00:17:14,900 --> 00:17:25,869
I think what we want our audience to really wrap their heads around is that PGX is just a piece of that larger puzzle um from diagnosis to treatment to,

251
00:17:25,880 --> 00:17:26,910
to remission.

252
00:17:27,239 --> 00:17:29,880
So I think you guys are absolutely,

253
00:17:29,890 --> 00:17:31,579
you're already in the future.

254
00:17:31,589 --> 00:17:32,849
In other words,

255
00:17:32,859 --> 00:17:33,130
you know,

256
00:17:33,140 --> 00:17:39,689
you're already providing all these different uh tests um like you mentioned to,

257
00:17:39,699 --> 00:17:44,310
to facilitate from diagnosis to remission to remission.

258
00:17:44,660 --> 00:17:45,520
That's correct.

259
00:17:45,530 --> 00:17:45,829
Yeah.

260
00:17:46,349 --> 00:17:55,089
So um you've given us so much great information about uh the tests that that you guys offer.

261
00:17:55,329 --> 00:18:02,060
Can you explain to our audience um your newest test?

262
00:18:02,069 --> 00:18:03,859
Uh the responder test.

263
00:18:04,150 --> 00:18:12,979
And um what role it will play in the paradigm from the diagnosis of IBD to remission?

264
00:18:14,050 --> 00:18:14,260
Yeah,

265
00:18:14,270 --> 00:18:14,760
sure.

266
00:18:14,770 --> 00:18:15,569
So we,

267
00:18:15,579 --> 00:18:18,069
we are doing things a little bit different than other.

268
00:18:18,079 --> 00:18:19,489
We do believe that uh you know,

269
00:18:19,500 --> 00:18:21,449
the it has to be simple.

270
00:18:21,459 --> 00:18:24,189
Uh uh We can obviously construct some very,

271
00:18:24,199 --> 00:18:33,530
very complex algorithm and there are some tests that do that with a very sophisticated machine learning based tools that are available using neural networks,

272
00:18:33,540 --> 00:18:33,729
you know,

273
00:18:33,739 --> 00:18:34,790
those sorts of things.

274
00:18:34,800 --> 00:18:39,729
But we have taken on a different approach where with the responder test,

275
00:18:39,739 --> 00:18:40,329
we are basically,

276
00:18:40,339 --> 00:18:45,160
we are taking an approach which is very simple to address the first and foremost.

277
00:18:45,170 --> 00:18:53,020
Most important aspect of responding uh predicting response to uh to medication is the pharmacokinetics.

278
00:18:53,280 --> 00:19:03,250
Uh You cannot be responding to a drug if the drug is not given and you obviously cannot respond to a drug if the drug is not metabolized adequately.

279
00:19:03,359 --> 00:19:06,349
And this is what we are doing with the responder test.

280
00:19:06,579 --> 00:19:09,010
We are addressing some uh uh you know,

281
00:19:09,020 --> 00:19:11,630
fundamental issues with those uh biologist,

282
00:19:11,640 --> 00:19:12,410
for example,

283
00:19:12,660 --> 00:19:15,170
uh the anti tumor necrosis factors.

284
00:19:15,180 --> 00:19:15,650
So,

285
00:19:15,750 --> 00:19:19,199
such as uh Infliximab and Adalimumab,

286
00:19:19,209 --> 00:19:23,050
it is well known uh that uh uh those drugs,

287
00:19:23,060 --> 00:19:25,689
first of all are prone to immunization.

288
00:19:25,989 --> 00:19:36,949
Uh Meaning that uh uh the drug itself uh is recognized by the immune system uh and digested by the antigen presenting cells.

289
00:19:36,959 --> 00:19:42,209
If you will uh where you gonna have uh uh an immune uh uh response,

290
00:19:42,380 --> 00:19:56,979
uh mounted a cancer drug to produce uh immunogen that will severely impact its pharmacokinetics where the labels will be inadequate to produce uh the desired uh anti-inflammatory effects.

291
00:19:56,989 --> 00:19:57,150
So,

292
00:19:57,160 --> 00:19:58,890
we are with the risk conductors,

293
00:19:58,900 --> 00:20:01,040
we are combining two things together.

294
00:20:01,189 --> 00:20:07,959
First of all is the genetic test itself which uh predicts the risk of immun immunization.

295
00:20:07,969 --> 00:20:18,010
The name of the test is on HL A uh DQ A 105 ali uh that uh uh promotes the presentation of the,

296
00:20:18,020 --> 00:20:19,130
of the,

297
00:20:19,140 --> 00:20:19,910
of Infliximab,

298
00:20:20,010 --> 00:20:20,750
for example,

299
00:20:20,760 --> 00:20:32,130
to the T cell repertoire in order to uh promote the Ronon expansion and the formation of the anti antibodies together with uh another dimension which is the clearance,

300
00:20:32,140 --> 00:20:33,670
which is as important.

301
00:20:33,949 --> 00:20:36,209
Uh One of the key issue is the,

302
00:20:36,219 --> 00:20:36,770
the,

303
00:20:36,780 --> 00:20:41,239
the monoclonal antibodies and uh such as Infliximab or Adalimumab.

304
00:20:41,329 --> 00:20:42,280
But in fact,

305
00:20:42,290 --> 00:20:45,890
a neon antibodies that those drugs are uh you know,

306
00:20:45,900 --> 00:20:49,010
cleared and consumed uh from the,

307
00:20:49,020 --> 00:20:50,949
from the central compartment if you will,

308
00:20:50,959 --> 00:20:54,520
since we are doing a little bit of uh uh pharmacokinetics here.

309
00:20:54,530 --> 00:20:56,020
And uh uh you know,

310
00:20:56,030 --> 00:21:06,670
if the patient present who is uh a high degree of inflammatory burden is gonna have uh the patient will have a high clearance and that's gonna worsen uh in the,

311
00:21:06,680 --> 00:21:13,939
in the presence again of the HL AD Q A 105 genetic marker that uh associate with uh immunization.

312
00:21:13,949 --> 00:21:16,859
So I but this is a combination of both,

313
00:21:17,199 --> 00:21:19,359
these are the predictive factors of pharmacokinetic,

314
00:21:20,359 --> 00:21:38,209
which we combine together where the patient presenting with a risk of immunization as well as accelerated clearance due to the fact that the patient has high inflammation or due to the fact that they are so intrinsic pharmacokinetic properties that makes that the patient,

315
00:21:38,219 --> 00:21:38,300
you know,

316
00:21:38,310 --> 00:21:39,479
will clear the drug very,

317
00:21:39,489 --> 00:21:40,260
very fast.

318
00:21:40,560 --> 00:21:41,670
For example,

319
00:21:41,680 --> 00:21:46,819
due to the inefficient uh recirculation of the drug itself with the new,

320
00:21:46,869 --> 00:21:46,930
the,

321
00:21:46,939 --> 00:21:50,599
the the in the reticular on the system.

322
00:21:50,920 --> 00:21:51,619
Together,

323
00:21:51,630 --> 00:22:02,109
those patients presenting with uh uh together these uh poor prognostic factor of pharmacokinetic origin will tend to be severely underdose,

324
00:22:02,380 --> 00:22:06,719
will not be responding to the drug uh adequately as and they,

325
00:22:06,729 --> 00:22:10,719
and they probably should in the first place if you are able to address uh you know,

326
00:22:10,729 --> 00:22:12,270
the the the exposure.

327
00:22:12,439 --> 00:22:14,079
So what we do with this test,

328
00:22:14,089 --> 00:22:21,640
we will be able to inform uh the clinic that the patient is at risk of achieving,

329
00:22:21,650 --> 00:22:30,829
of achieving suboptimal pharmacokinetics and therefore being able to adjust the dose uh uh to start with more adequately.

330
00:22:30,839 --> 00:22:38,650
So that the the the proper uh exposure is achieved uh during induction to again to,

331
00:22:38,660 --> 00:22:39,040
to,

332
00:22:39,050 --> 00:22:39,380
to,

333
00:22:39,390 --> 00:22:40,890
to achieve a better outcome.

334
00:22:41,040 --> 00:22:47,270
And I think the pharmacist will have a very important role to play here in terms of absolutely,

335
00:22:47,280 --> 00:22:51,239
that information is priceless in the management of these medications.

336
00:22:51,250 --> 00:22:54,930
So thanks for elaborating on that.

337
00:22:56,010 --> 00:22:59,040
And if I may add in our previous conversation,

338
00:22:59,050 --> 00:23:00,810
uh before the recording of podcast,

339
00:23:00,819 --> 00:23:08,869
we had discussed um you guys' robust platform for collaborating with payers to obtain market access and reimbursements for the test.

340
00:23:09,109 --> 00:23:14,109
But without stealing the Thunder from uh Prometheus market access and reimbursement team,

341
00:23:14,199 --> 00:23:22,619
can you please uh briefly detail how Prometheus has proactively worked with payers to solve the problem.

342
00:23:22,920 --> 00:23:27,349
Um the population health problem by building the evidence payers want,

343
00:23:27,359 --> 00:23:41,170
want to see um about your test before you go to the market and then build the test and then hope the payers will see the value and the result and then that will improve the market access and reimbursement for your um precision medicine test.

344
00:23:42,160 --> 00:23:42,339
Yeah.

345
00:23:42,349 --> 00:23:43,180
So briefly I can,

346
00:23:43,189 --> 00:23:43,579
I'm,

347
00:23:43,589 --> 00:23:46,619
I'm probably not the right person to answer that question.

348
00:23:46,630 --> 00:23:47,369
We have a very,

349
00:23:47,380 --> 00:23:52,400
very efficient market access group uh uh pro meters that does a splendid job.

350
00:23:52,410 --> 00:23:59,780
But uh uh uh what I can tell you that we have an evidence uh uh development plan in place where we,

351
00:23:59,790 --> 00:24:14,000
we are establishing the clinical utility of our testing solution by demonstrating uh the payer value uh with respect of uh patient management and uh uh and the,

352
00:24:14,010 --> 00:24:16,630
and the impact of our technology on the,

353
00:24:16,640 --> 00:24:18,119
on physician behavior.

354
00:24:18,430 --> 00:24:21,319
Uh We have uh uh already uh you know,

355
00:24:21,329 --> 00:24:25,160
commercialized uh two of those tests for which we have initiated,

356
00:24:25,170 --> 00:24:29,040
initiated the Power studies uh that uh uh you know,

357
00:24:29,050 --> 00:24:32,000
already provide uh you know,

358
00:24:32,104 --> 00:24:34,484
differentiated and the value to,

359
00:24:34,494 --> 00:24:35,915
to the payer where we are,

360
00:24:35,925 --> 00:24:36,025
the,

361
00:24:36,035 --> 00:24:46,005
the clinicians are basically using our technology to make treatment decision uh as well as uh some prospective clinicality study which we are initiating,

362
00:24:46,145 --> 00:24:47,555
initiating to.

363
00:24:47,564 --> 00:24:48,574
Um uh again,

364
00:24:48,584 --> 00:24:49,425
demonstrate the,

365
00:24:49,435 --> 00:24:49,915
the,

366
00:24:49,925 --> 00:24:50,244
the,

367
00:24:50,255 --> 00:24:53,594
the payer value you uh uh we can certainly follow up with,

368
00:24:53,604 --> 00:24:58,755
uh you can certainly follow up with our market access group uh uh as appropriate there.

369
00:24:58,765 --> 00:25:00,765
Uh They can fill you with more information.

370
00:25:01,349 --> 00:25:01,589
No,

371
00:25:01,599 --> 00:25:02,520
that totally makes sense.

372
00:25:02,530 --> 00:25:03,310
That totally makes sense.

373
00:25:03,319 --> 00:25:10,890
But um we're excited that you're also farm d So how did you get to this role of outside the box path?

374
00:25:10,900 --> 00:25:11,550
There?

375
00:25:11,640 --> 00:25:17,530
There may be a pharmacist student or pharmacist wanting to switch or transition into a role such as yours,

376
00:25:17,540 --> 00:25:19,609
which is a Chief Scientific Officer.

377
00:25:19,619 --> 00:25:20,609
I want to learn more.

378
00:25:20,619 --> 00:25:23,920
So how would you um can you talk a little bit about that?

379
00:25:24,560 --> 00:25:24,780
Well,

380
00:25:24,790 --> 00:25:26,270
we are clinical laboratories.

381
00:25:26,280 --> 00:25:29,400
So in order to uh uh to be in my role,

382
00:25:29,410 --> 00:25:34,020
you need to have uh uh you need to have expertise in clinical laboratory science.

383
00:25:34,030 --> 00:25:36,140
So for the students is basically,

384
00:25:36,150 --> 00:25:36,300
you know,

385
00:25:36,310 --> 00:25:40,770
to do the family degree and then complete the family degree with uh a doctorate,

386
00:25:40,780 --> 00:25:40,930
you know,

387
00:25:40,939 --> 00:25:44,260
which is uh focus on clinical laboratory science.

388
00:25:44,270 --> 00:25:46,079
So you can achieve uh uh you know,

389
00:25:46,089 --> 00:25:47,640
the all the elements you need to be,

390
00:25:47,650 --> 00:25:48,219
for example,

391
00:25:48,229 --> 00:25:53,189
board certified uh as uh as as medical laboratory director.

392
00:25:53,199 --> 00:25:55,160
So you can uh uh so,

393
00:25:55,170 --> 00:25:55,589
uh yeah,

394
00:25:55,599 --> 00:25:56,030
this is,

395
00:25:56,040 --> 00:25:56,400
this is,

396
00:25:56,410 --> 00:25:57,209
this is uh you know,

397
00:25:57,219 --> 00:25:59,160
a great opportunity I think for pharmacies,

398
00:25:59,170 --> 00:26:10,800
there is an absolute need to uh have the clinical pharmacist provide uh uh drug information to healthcare professional as well as uh assist patient with the monitoring of their disease,

399
00:26:10,810 --> 00:26:15,229
the effectiveness of the therapy and um and uh you know,

400
00:26:15,239 --> 00:26:16,060
monitoring the,

401
00:26:16,069 --> 00:26:20,969
the side effect and the toxicity from uh from those uh those medication.

402
00:26:24,650 --> 00:26:24,959
Well,

403
00:26:24,969 --> 00:26:32,119
the I know our audience is going to have uh additional questions for you.

404
00:26:32,130 --> 00:26:32,540
I mean,

405
00:26:32,989 --> 00:26:35,609
you've provided them with so much great information,

406
00:26:35,619 --> 00:26:44,959
but it's only the beginning of what they could possibly learn um about um the testing that you do for IBD and,

407
00:26:44,969 --> 00:26:46,729
and even your career path.

408
00:26:47,050 --> 00:26:47,530
So,

409
00:26:47,540 --> 00:26:49,300
if you wouldn't mind telling us,

410
00:26:49,310 --> 00:26:51,359
um because we have to wrap up,

411
00:26:51,369 --> 00:26:52,670
unfortunately,

412
00:26:53,150 --> 00:26:55,810
this episode of the podcast,

413
00:26:55,819 --> 00:27:00,250
uh could you tell us how our audience members might be able to contact you directly.

414
00:27:01,260 --> 00:27:01,449
Yeah,

415
00:27:01,459 --> 00:27:07,079
I can be contacted on my uh on my email at TT W at como slab dot com.

416
00:27:07,949 --> 00:27:08,810
All right.

417
00:27:09,069 --> 00:27:09,300
Well,

418
00:27:09,310 --> 00:27:14,290
thank you again so much uh for joining us on this episode.

419
00:27:14,300 --> 00:27:15,290
We really,

420
00:27:15,300 --> 00:27:29,530
really hope that our listeners um ideas of not only what PGX can be but how PGX can be utilized in a comprehensive testing suite.

421
00:27:29,709 --> 00:27:35,670
We really hope that our a our audience will um listen in and learn this information.

422
00:27:36,280 --> 00:27:37,869
Um And to our audience,

423
00:27:37,880 --> 00:27:39,439
thank you for tuning in.

424
00:27:39,449 --> 00:27:42,619
We really hope that you've learned from this episode.

425
00:27:43,130 --> 00:27:46,339
Uh We do a whole lot of PG Xing here on this podcast.

426
00:27:46,349 --> 00:27:48,380
We talk about PGX Science,

427
00:27:48,390 --> 00:27:52,030
clinical application and the business of PGX.

428
00:27:52,260 --> 00:27:54,880
So we'd love to hear about from you.

429
00:27:55,099 --> 00:27:56,479
I love to hear from you.

430
00:27:56,489 --> 00:27:58,439
Um What can we teach you?

431
00:27:58,449 --> 00:28:00,920
What more can we teach you through our podcast?

432
00:28:00,930 --> 00:28:12,349
So please drop us a message on linkedin and let us know and please share this link to this podcast link episode with everyone so they can tune in and listen to the PGX for promises podcast.

433
00:28:12,520 --> 00:28:15,369
Leave us a review on Apple podcast or Spotify.

434
00:28:15,459 --> 00:28:18,130
And you can also visit us on PGX four,

435
00:28:18,140 --> 00:28:22,989
the number four Rx dot com to listen to all our other episodes.

436
00:28:23,000 --> 00:28:23,079
Well,

437
00:28:23,089 --> 00:28:23,790
thank you.

438
00:28:24,199 --> 00:28:28,750
Thanks for your interest in PGX and for spending some time with us.

439
00:28:28,760 --> 00:28:35,670
Please share this podcast and leave us a review on Apple podcasts or Spotify for all of our episodes.

440
00:28:35,680 --> 00:28:39,390
Please visit PGX four Rx dot com.

441
00:28:39,569 --> 00:28:43,380
That's PGX four Rx dot com.